IL330346A - Methods of treating the disease using LEVOKETOCONAZOLE - Google Patents

Methods of treating the disease using LEVOKETOCONAZOLE

Info

Publication number
IL330346A
IL330346A IL330346A IL33034626A IL330346A IL 330346 A IL330346 A IL 330346A IL 330346 A IL330346 A IL 330346A IL 33034626 A IL33034626 A IL 33034626A IL 330346 A IL330346 A IL 330346A
Authority
IL
Israel
Prior art keywords
levoketoconazole
methods
treating disease
disease
treating
Prior art date
Application number
IL330346A
Other languages
English (en)
Hebrew (he)
Inventor
Cohen Fredric
Original Assignee
Strongbridge Dublin Ltd
Cohen Fredric
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72338256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL330346(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Strongbridge Dublin Ltd, Cohen Fredric filed Critical Strongbridge Dublin Ltd
Publication of IL330346A publication Critical patent/IL330346A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL330346A 2019-03-04 2020-03-02 Methods of treating the disease using LEVOKETOCONAZOLE IL330346A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962813399P 2019-03-04 2019-03-04
PCT/US2020/020644 WO2020180784A1 (en) 2019-03-04 2020-03-02 Methods of treating disease with levoketoconazole

Publications (1)

Publication Number Publication Date
IL330346A true IL330346A (en) 2026-08-01

Family

ID=72338256

Family Applications (2)

Application Number Title Priority Date Filing Date
IL330346A IL330346A (en) 2019-03-04 2020-03-02 Methods of treating the disease using LEVOKETOCONAZOLE
IL286099A IL286099A (en) 2019-03-04 2021-09-02 Methods of treating disease with levoketoconazole

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL286099A IL286099A (en) 2019-03-04 2021-09-02 Methods of treating disease with levoketoconazole

Country Status (10)

Country Link
US (5) US11020393B2 (cg-RX-API-DMAC7.html)
EP (1) EP3934649A4 (cg-RX-API-DMAC7.html)
JP (3) JP7574204B2 (cg-RX-API-DMAC7.html)
KR (2) KR102950333B1 (cg-RX-API-DMAC7.html)
CN (1) CN113710250A (cg-RX-API-DMAC7.html)
AU (2) AU2020232246B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021017561A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132319A1 (cg-RX-API-DMAC7.html)
IL (2) IL330346A (cg-RX-API-DMAC7.html)
WO (1) WO2020180784A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3934649A4 (en) * 2019-03-04 2022-11-23 Strongbridge Dublin Limited METHODS OF TREATMENT OF DISEASES WITH LEVOKETOCONAZOLE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101141964B (zh) * 2005-01-10 2013-06-05 科尔泰多投资公司 治疗糖尿病、代谢综合症和其它病症的组合物及方法
RU2009116632A (ru) * 2006-10-02 2010-11-10 Кортендо Инвест, Аб (Se) Энантиомер кетоконазола у людей
US9522432B2 (en) * 2012-06-01 2016-12-20 Herbert W. Staub Cradle cutter
TWI690521B (zh) * 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
WO2018106907A1 (en) * 2016-12-08 2018-06-14 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary
US10512667B2 (en) * 2017-06-27 2019-12-24 The Regents Of The University Of Michigan Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production
EP3934649A4 (en) * 2019-03-04 2022-11-23 Strongbridge Dublin Limited METHODS OF TREATMENT OF DISEASES WITH LEVOKETOCONAZOLE

Also Published As

Publication number Publication date
JP7801408B2 (ja) 2026-01-16
US11278547B2 (en) 2022-03-22
IL286099A (en) 2021-10-31
AU2020232246A1 (en) 2021-10-07
US20210267970A1 (en) 2021-09-02
KR102950333B1 (ko) 2026-04-08
US20250387389A1 (en) 2025-12-25
JP2022522873A (ja) 2022-04-20
EP3934649A1 (en) 2022-01-12
AU2020232246B2 (en) 2025-03-20
US20240148724A1 (en) 2024-05-09
WO2020180784A1 (en) 2020-09-10
EP3934649A4 (en) 2022-11-23
JP7574204B2 (ja) 2024-10-28
US11903940B2 (en) 2024-02-20
KR20210135278A (ko) 2021-11-12
JP2026082828A (ja) 2026-05-19
CA3132319A1 (en) 2020-09-10
AU2025204382A1 (en) 2025-07-03
US12377096B2 (en) 2025-08-05
KR20260049881A (ko) 2026-04-14
JP2025026838A (ja) 2025-02-26
US11020393B2 (en) 2021-06-01
US20220387425A1 (en) 2022-12-08
BR112021017561A2 (pt) 2021-11-09
US20200397781A1 (en) 2020-12-24
CN113710250A (zh) 2021-11-26